Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Fish oil could boost birth weight in HIV-Positive moms

NCT ID NCT06971445

Disease control Sponsor: Instituto Nacional de Perinatologia Isidro Espinosa de los Reyes Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only This study
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study tests whether taking omega-3 supplements (fish oil) for 8 weeks during pregnancy can help HIV-positive women on antiretroviral therapy have healthier babies. Researchers will measure birth weight, length of pregnancy, and inflammation levels. 92 pregnant women will be randomly assigned to receive either omega-3 or a placebo (olive oil).

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
omega-3 polyunsaturated fatty acids (EPA, DHA, ALA)
What this could lead to
If it works, this could point toward a simple dietary supplement to help HIV-positive women have healthier pregnancies and babies.
What could go wrong
This is a small, early-stage trial with only 92 participants, so results may not apply widely. The supplement may not significantly improve outcomes over placebo.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 92 people

The number the study aims to enrol. It can still change while the study runs.

Started

May 2025

Expected to finish

Dec 2029

An estimate. End dates often move.

Lead sponsor

A government agency

The lead sponsor is a government body.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Pregnant women * Single pregnancy * Gestational age from 20 to 29 weeks since the first day of the last menstrual period * Agree to participate in the study Exclusion Criteria: * Gestational age more than 29 weeks * With diagnosis of gestational diabetes or preeclampsia * Smoking and/or drug use during the invitation to participate in the study * Fish allergy

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Pregnant HIV positive women are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

HIV infectious disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Pregnant HIV positive women

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    The full official record for this study. This one lists no contact details, but it is the first place any would appear.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Instituto Nacional de Perinatologia

    Mexico City, Mexico City, 11000, Mexico

More trials for these conditions

Other studies related to the condition(s) this trial covers.